ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 11, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Oct 11, 2012
News
Merck Plans to Move Global Headquarters within New Jersey
By Jennifer Markarian
Merck has announced plans to close its headquarters in Whitehouse Station, New Jersey, and relocate to its existing facility in Summit, New Jersey, beginning in 2014.
Takeda to Acquire LigoCyte Pharmaceuticals
By Stephanie Sutton
Takeda's US subsidiary, Takeda America Holdings, has agreed to acquire the vaccine specialist company LigoCyte Pharmaceuticals for an upfront payment of $60 million in a move intended to bolster and expand the company's vaccine business.
Meningitis Outbreak Linked to Contaminated Vials of Steroid Injectables
By Jill Wechsler
A national fungal meningitis outbreak linked to contaminated vials of steroid injectables from a Massachusetts compounding operation has reignited the debate over the safety of compounded drugs and the need for stronger FDA regulation of these activities. Last week, the Centers for Disease Control and Prevention reported seven deaths and 91 ill.
Week of October 8, 2012: Mayne Pharma to Acquire Metrics; Sanofi, Bristol-Myers Squibb Restructure Plavix Alliance; and More
Mayne Pharma to Acquire Metrics; Sanofi, Bristol-Myers Squibb Restructure Plavix Alliance; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here